The ACCELERATE Trial

Nicholls_ACCELERATE

ePAPER READ

DOWNLOAD ePAPER

iciar.mar

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

START NOW

Systolic Blood Pressure During the Trial

134

Mean difference = 0.9 mm Hg (P

Recommendations
Info

Adverse Clinical and Biochemical Events Parameter Placebo Evacetrapib P Value Discontinuation due to adverse events 8.7% 8.6% 0.86 ALT >3x ULN 0.7% 0.6% 0.31 Bilirubin >2x ULN 0.3% 0.1% 0.06 CK >3x ULN 3.1 % 2.3%

Systolic Blood Pressure During the Trial 134 Mean difference = 0.9 mm Hg (P

Page 1 and 2: The ACCELERATE Trial Impact of the
Page 3 and 4: Role of Cholesteryl Ester Transfer
Page 5 and 6: ACCELERATE Trial Design 12,092 pati
Page 7 and 8: Baseline Clinical Characteristics P
Page 9 and 10: Adherence and Retention Placebo (n=
Page 11 and 12: Percent Change in LDL-C Levels Duri
Page 13: Secondary Efficacy Endpoints Placeb
Page 17: ACCELERATE Data Sharing Initiative

The ACCELERATE Trial

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?